LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

Inicio・Lista de Acciones・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Abierto

SectorSalud

9.92 0.3

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

9.76

Máximo

9.92

Métricas clave
By Trading Economics
Ingresos	42M 17M
Ventas	14M 169M
BPA	0.17
Margen de beneficio	10.237
Empleados	499
EBITDA	54M 48M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+61.22% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	693M 3B
Apertura anterior	9.62
Cierre anterior	9.92

Noticias sobre sentimiento de mercado

By Acuity

12%

88%

16 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

5.925 / 7.38 Soporte y Resistencia

Amicus Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 dic 2025, 23:58 UTC

Adquisiciones, fusiones, absorciones

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11 dic 2025, 23:56 UTC

Ganancias

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11 dic 2025, 23:03 UTC

Adquisiciones, fusiones, absorciones

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11 dic 2025, 22:06 UTC

Adquisiciones, fusiones, absorciones

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dic 2025, 21:50 UTC

Ganancias

Costco Same-Store Sales, Membership Fees Rose in 1Q

11 dic 2025, 23:45 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

11 dic 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11 dic 2025, 23:37 UTC

Charlas de Mercado

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11 dic 2025, 23:31 UTC

Ganancias

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dic 2025, 22:48 UTC

Adquisiciones, fusiones, absorciones

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11 dic 2025, 22:35 UTC

Ganancias

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11 dic 2025, 22:30 UTC

Ganancias

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11 dic 2025, 22:09 UTC

Adquisiciones, fusiones, absorciones

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11 dic 2025, 22:06 UTC

Adquisiciones, fusiones, absorciones

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11 dic 2025, 22:05 UTC

Ganancias

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dic 2025, 21:51 UTC

Adquisiciones, fusiones, absorciones

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dic 2025, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

11 dic 2025, 21:39 UTC

Ganancias

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11 dic 2025, 21:39 UTC

Ganancias

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11 dic 2025, 21:38 UTC

Ganancias

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11 dic 2025, 21:37 UTC

Ganancias

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11 dic 2025, 21:37 UTC

Charlas de Mercado

Broadcom Sees AI Revenue Doubling -- Market Talk

11 dic 2025, 21:34 UTC

Adquisiciones, fusiones, absorciones

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11 dic 2025, 21:29 UTC

Adquisiciones, fusiones, absorciones

Dexus Aiming for Long-Term Holding of A$50M in Fund

11 dic 2025, 21:28 UTC

Charlas de Mercado

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11 dic 2025, 21:28 UTC

Adquisiciones, fusiones, absorciones

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11 dic 2025, 21:28 UTC

Adquisiciones, fusiones, absorciones

Dexus: Third Party Investors to Contribute Remainder

11 dic 2025, 21:27 UTC

Adquisiciones, fusiones, absorciones

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11 dic 2025, 21:26 UTC

Adquisiciones, fusiones, absorciones

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11 dic 2025, 21:25 UTC

Adquisiciones, fusiones, absorciones

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Comparación entre iguales

Cambio de precio

Amicus Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

61.22% repunte

Estimación a 12 meses

Media 15.88 USD 61.22%

Máximo 21 USD

Mínimo 11 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Amicus Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Amicus Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

5.925 / 7.38Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

16 / 374 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.